WASHINGTON, Dec. 7, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY ® (ponesimod) from Actelion Pharmaceuticals Ltd.
WASHINGTON, Jan. 25, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Patent and Trademark Office has issued a notice of allowance for its PONVORY ® ...
Vanda Pharmaceuticals Inc (NASDAQ:VNDA) has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd, a Johnson & Johnson company (NYSE:JNJ). The FDA and Health ...
We expect investors to focus on the sales performance of Vanda Pharmaceuticals Inc.’s VNDA portfolio of marketed drugs, Hetlioz, Fanapt and Ponvory, as well as updates on pipeline development and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results